(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 June 2022 (23.06.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/133324 A1

(51) International Patent Classification:
A61K 9/08 (2006.01) *A61P 7/04* (2006.01)
A61K 48/00 (2006.01) *A61K 47/02* (2006.01)
A61K 47/26 (2006.01) *A61K 47/10* (2017.01)

(21) International Application Number:
PCT/US2021/064222

(22) International Filing Date:
17 December 2021 (17.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/127,826 18 December 2020 (18.12.2020) US

(71) Applicants: **SANGAMO THERAPEUTICS, INC.** [US/US]; 7000 Marina Boulevard, Brisbane, California 94005 (US). **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors: **CONNER, Jessica Eileen**; c/o Pfizer Inc., 875 Chesterfield Parkway West, Chesterfield, Missouri 63017 (US). **CRAWFORD, Lindsey Anne**; c/o Pfizer Inc., 1 Burtt Road, Andover, Massachusetts 01801 (US). **DAMITZ, Robert**; c/o Sangamo Therapeutics, Inc., 7000 Marina Boulevard, Brisbane, California 94005 (US). **DAVIS, Brendan Michael**; c/o Pfizer Inc., 1 Burtt Road, Andover, Massachusetts 01810 (US). **HODGE, Cody Michael**; c/o Pfizer Inc., 875 Chesterfield Parkway West, Chesterfield, Missouri 63017 (US). **KIMMEL II, Michael Leland**; c/o Pfizer Inc., 875 Chesterfield Parkway West, Chesterfield, Missouri 63017 (US). **QURESHI WILLARD, Tihami**; c/o Pfizer Inc., 875 Chesterfield Parkway West, Chesterfield, Missouri 63017 (US). **RAMSEY, Phillip**; c/o Sangamo Therapeutics, Inc., 7000 Marina Boulevard, Brisbane, California 94005 (US). **THORNE, Daniel Joseph**; c/o Pfizer Inc., 875 Chesterfield Parkway West, Chesterfield, Missouri 63017 (US). **YOUNG, Anthony Lee**; c/o Pfizer Inc., 875 Chesterfield Parkway West, Chesterfield, Missouri 63017 (US).

(74) Agent: **LI, Z. Ying** et al.; Steptoe & Johnson LLP, 1330 Connecticut Avenue, N.W., Washington, District of Columbia 20036 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: IMPROVED PHARMACEUTICAL COMPOSITIONS CONTAINING ADENO-ASSOCIATED VIRAL VECTOR

(57) Abstract: The present invention provides compositions comprising a recombinant AAV and one or more pharmaceutically acceptable excipients. The compositions have improved stability and shelf life as compared to other AAV compositions.

WO 2022/133324 A1